BISPECIFIC ANTIBODY TARGETING A COMPLEMENT FACTOR OR COMPLEMENT REGULATORY PROTEIN

• US 20130123473A1
• Filed: 12/17/2012
• Published: 05/16/2013
• Est. Priority Date: 12/08/2004
• Status: Abandoned Application

• Current Assignee: Immunomedics, Inc.
• Original Assignee: Immunomedics, Inc.
• Inventors: GOLDENBERG, David M., HANSEN, Hans J.
• Application Number:
  US13/717,230
• Publication Number:
  US 20130123473A1
• Time in Patent Office: Days
• US Class Current: 530/391.3
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 38/4866 Protein C (3.4.21.69)
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/40 bacterial
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C07K 16/1203 : from Gram-negative bacteria
• CPC Class Codes: C07K 16/24 : against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 16/241 : Tumor Necrosis Factors
• CPC Class Codes: C07K 16/248 : IL-6
• CPC Class Codes: C07K 16/2803 : against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2896 : against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/30 : from tumour cells
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 : multispecific
• CPC Class Codes: C07K 2317/734 : Complement-dependent cytotoxicity [CDC]

Abstract

A multispecific antagonist is disclosed that reacts specifically with at least two different targets. The targets are (A) proinflammatory effectors of the innate immune system, (B) coagulation factors, (C) complement factors and complement regulatory proteins, and (D) targets specifically associated with an inflammatory or immune-dysregulatory disorder or with a pathologic angiogenesis or cancer, wherein this latter target is not (A), (B) or (C). At least one of the targets is (C), and when the multispecific antagonist comprises a single multispecific antibody, then CD74 is excluded as a target of said antagonist. When the multispecific antagonist comprises a combination of separate antibodies, combinations are excluded where one of said antibodies targets a B-cell antigen and the other antibody targets a T-cell, plasma cell, macrophage or inflammatory cytokine and combinations are also excluded where one of said antibodies targets CD20 and the other antibody targets C3b or CD40.

Claims

1. A bispecific antibody that binds with two different targets, wherein said targets are selected from (i) a complement factor and (ii) a target associated with septicemia, sepsis or septic shock selected from the group consisting of LPS, HMGB-1, MIF, TNFα

, TF, VEGF, and IL-6, wherein said bispecific antibody is an immunoconjugate that comprises a diagnostic/detection agent or a therapeutic agent.

2. A bispecific antibody according to claim 1, wherein one arm of said antibody reacts specifically with a complement factor.

3. A bispecific antibody according to claim 1, additionally comprising a secondary therapeutic which (i) is a cytokine or a chemokine, (ii) affects coagulation or (iii) affects T cells or B-cells.

4. A bispecific antibody according to claim 1, additionally comprising a secondary therapeutic that affects coagulation.

5. A bispecific antibody according to claim 1, additionally comprising a secondary therapeutic that affects T cells or B cells.

6. A bispecific antibody according to claim 1, additionally comprising a cytokine or chemokine.

7. A bispecific antibody according to claim 1, wherein said bispecific antibody is an immunoconjugate that comprises a therapeutic agent.

8. A bispecific antibody according to claim 1, wherein (ii) is a target selected from the group consisting of HMGB-1, MIF, and TF.

9. A bispecific antibody according to claim 1, wherein said bispecific antibody reacts with MIF and a complement factor selected from the group consisting of C3, C5, C3a, and CSa.

10. A bispecific antibody according to claim 1, wherein said bispecific antibody reacts with LPS and a complement factor selected from the group consisting of C3, C5, C3a, and CSa.

11. A bispecific antibody according to claim 1, wherein said bispecific antibody reacts with TF and a complement factor selected from the group consisting of C3, C5, C3a, and CSa.

12. A bispecific antibody according to claim 1, wherein said bispecific antibody reacts with TNFα

and a complement factor selected from the group consisting of C3, C5, C3a, and CSa.